The proteome is a major determinant of the behaviour of cells and tissues in health and disease, and it may therefore be expected that quantitative proteomic analyses will be a powerful diagnostic and treatment-decision support tool in many medical disciplines. In the cancer clinic, for example, proteomics should be able to predict treatment response and thus aid clinicians select the most effective cancer treatments for individual patients. However, quantitative proteomic analyses are not yet in mainstream routine clinical use.
This one-day symposium will bring together researchers from various areas of medicine to present the progress they have made with the use of quantitative proteomics for diagnosis of disease, discovery of predictive and prognostic biomarkers, increasing the molecular understanding of disease states, identification of treatment targets, and potential implications for personalised medicine. There will be a brief update on the progress of the ProCan research program. Speakers will also discuss the most effective approaches for implementing proteomics in the clinic.